Abstract
Diagnosing subjects in complex genetic diseases is a very challenging task. Computational methodologies exploit information at genotype level by taking into account single nucleotide polymorphisms (SNP). They leverage the result of genome-wide association studies analysis to assign a statistical significance to each SNP. Recent methodologies extend such an approach by aggregating SNP significance at genetic level in order to identify genes that are related to the condition under study. However, such methodologies still suffer from the initial single-SNP analysis. Here, we present DiGAS, a tool for diagnosing genetic conditions by computing significance, by means of SNP information, but directly at the gene level. Such an approach is based on a generalized notion of allele spectrum, which evaluates the complete genetic alterations of the SNP set composing a gene at population level. Statistical significance of a gene is then evaluated by means of a differential analysis between the healthy and ill portions of the population. Tests, performed on well-established data sets regarding Alzheimer’s disease, show that DiGAS outperforms the state-of-the-art in distinguishing between ill and healthy subjects.
Highlights
We introduce a new generalized version of allele frequency spectrum.
We propose a methodology, called DiGAS, based on the new defined genomic information and independent from GWAS analysis that out-performs existing methods in distinguish healthy/ill subjects with a speed up of 5x.
On a reference Alzheimer’s disease genomic datasets, ADNI, DiGAS reaches F1 score up to 0.92.
DiGAS methodology manages any type of genomic features, such as genes, exons, upstream/downstream regions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Computer Science Department, University of Verona, Verona 37134, Italy
Data Availability
All data produced in the present study are available upon reasonable request to the authors
